ArticleArteriosclerosis, thrombosis, and vascular biology2019
AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease.Frontiers in cardiovascular medicine · 2025Review
- Factor XI: structure, function and therapeutic inhibition.Journal of thrombosis and thrombolysis · 2024Review
- The third-generation anticoagulants: factors XI, XII, and XIII inhibitors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings.Haematologica · 2024Review
- Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism.Hematology. American Society of Hematology. Education Program · 2022Article
- Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.Frontiers in cardiovascular medicine · 2022Review
- Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence.Frontiers in cardiovascular medicine · 2022Review
- Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).Expert opinion on therapeutic patents · 2020Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.